338 related articles for article (PubMed ID: 9406266)
1. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Dellva MA; Tran P; Tollefson GD; Wentley AL; Beasley CM
Psychiatr Serv; 1997 Dec; 48(12):1571-7. PubMed ID: 9406266
[TBL] [Abstract][Full Text] [Related]
2. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
Tran PV; Dellva MA; Tollefson GD; Wentley AL; Beasley CM
Br J Psychiatry; 1998 Jun; 172():499-505. PubMed ID: 9828990
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
Jones B; Taylor CC; Meehan K
J Clin Psychiatry; 2001; 62 Suppl 2():22-4. PubMed ID: 11232747
[TBL] [Abstract][Full Text] [Related]
4. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
[TBL] [Abstract][Full Text] [Related]
7. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
Tohen M; Sanger TM; McElroy SL; Tollefson GD; Chengappa KN; Daniel DG; Petty F; Centorrino F; Wang R; Grundy SL; Greaney MG; Jacobs TG; David SR; Toma V
Am J Psychiatry; 1999 May; 156(5):702-9. PubMed ID: 10327902
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
[TBL] [Abstract][Full Text] [Related]
12. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
Gomez JC; Crawford AM
J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
Hamilton SH; Revicki DA; Genduso LA; Beasley CM
Neuropsychopharmacology; 1998 Jan; 18(1):41-9. PubMed ID: 9408917
[TBL] [Abstract][Full Text] [Related]
14. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
Tollefson GD; Sanger TM
Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.
Beasley CM; Sutton VK; Hamilton SH; Walker DJ; Dossenbach M; Taylor CC; Alaka KJ; Bykowski D; Tollefson GD;
J Clin Psychopharmacol; 2003 Dec; 23(6):582-94. PubMed ID: 14624189
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
[TBL] [Abstract][Full Text] [Related]
18. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
[TBL] [Abstract][Full Text] [Related]
19. Dosing the antipsychotic medication olanzapine.
Nemeroff CB
J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]